November 21, 2024
Cancer drug resistance is an area of high unmet medical need, impacting the success of therapeutics and contributing to cancer-related deaths. Resistance can be challenging to understand, model, and target due to its multifaceted complexity.
Rajendra Kumari, PhD, Executive Director, Integrated Solutions, Crown Bioscience
As Executive Director of Integrated Solutions within the Commercial and Strategic Development team, Rajendra leads the focus of cross-disciplinary solutions for drug discovery and development. She has over 20 years of oncology research experience with a Ph.D. in Molecular Pharmacology from the University of Leicester (UK). Prior to joining Crown Bioscience, Rajendra held post-doctoral fellowships and an Assistant Professor position in the Division of Preclinical Oncology within the Medical School, University of Nottingham, where she developed in vitro and in vivo preclinical models, including patient-derived systems and imaging capabilities. Rajendra also co-founded PRECOS Ltd. in 2010, serving as COO and then following the merger with Crown Bioscience, as CSO and General Manager for Crown Bioscience UK. In 2018, Rajendra became the Global Head of Scientific Communications for all platforms at Crown Bioscience Inc., working closely with multiple divisions and global departments to support the commercialization of R&D activity and capabilities. Rajendra is a member of the AACR and BACR and has authored over 40 abstracts and publications.
Your privacy is important to us.
We'll never share your information.
© 2024 Crown Bioscience. All Rights Reserved.
© 2024 Crown Bioscience. All Rights Reserved. Privacy Policy
2024-10-17
2024-04-02
landing_page
Integrated Solutions - Drug Resistance